Skip to content
Comparison

MK-677 (Ibutamoren) vs NAD+

MK-677 (Ibutamoren) and NAD+ are commonly compared for metabolic-support frameworks with different primary targets. MK-677 (Ibutamoren) is usually favored for body-composition goal specificity (proxy for metabolic intervention), while NAD+ is often preferred for cellular energy restoration emphasis. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For metabolic-support frameworks with different primary targets, the better choice depends on your primary endpoint. MK-677 (Ibutamoren) is stronger when the priority is weight-composition oriented protocols. NAD+ is stronger when the priority is energy and mitochondrial support priorities. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaMK-677 (Ibutamoren)NAD+
Primary mechanismOral ghrelin-receptor agonist GH secretagogueCoenzyme replenishment strategy for mitochondrial and metabolic pathways
Strongest clinical signalRaises GH/IGF-1 with oral convenienceSignals for improved cellular energetics and metabolic resilience
Typical dosing context10-25 mg once dailyIV, IM, SC, or oral precursor protocols vary widely
AdministrationOral dailyClinic infusions/injections or oral support stacks
Evidence quality gradeModerate human data in aging/body composition contextsModerate mechanistic evidence; heterogeneous clinical outcomes
Regulatory statusInvestigational, not FDA-approvedNot an FDA-approved disease-specific peptide therapy
Side-effect burdenAppetite, edema, and insulin-resistance concernsGenerally tolerated; protocol quality and formulation matter
Cost/access contextOften lower cost than injectable GH pathwaysHigh for infusion-heavy protocols
Best candidate profileUsers valuing oral administration over injectionsEnergy/fatigue and metabolic-support strategies
Main limitationMetabolic side effects may limit long-term useOutcome heterogeneity and protocol standardization gaps
Best use case in this comparisonweight-composition oriented protocolsenergy and mitochondrial support priorities

When to Choose Each

Choose MK-677 (Ibutamoren)

Best for weight-composition oriented protocols.

Choose NAD+

Best for energy and mitochondrial support priorities.

Verdict

If the main goal is weight-composition oriented protocols, MK-677 (Ibutamoren) is usually the better first-line choice. If the main goal is energy and mitochondrial support priorities, NAD+ is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. NNMT inhibition effectively activates NAD+ salvage pathway in adipocytes and prevents diet-induced obesity (2020) — PubMed
  2. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (2014) — PubMed
  3. Small molecule NNMT inhibitors for the treatment of obesity and metabolic syndrome (2021) — PubMed
  4. NAD+ metabolism and its roles in cellular processes during ageing (2018) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which has stronger evidence for metabolic-support frameworks with different primary targets — MK-677 (Ibutamoren) or NAD+?
MK-677 (Ibutamoren) is graded as moderate human data in aging/body composition contexts evidence in this context, while NAD+ is graded as moderate mechanistic evidence; heterogeneous clinical outcomes. In practice, strength depends on whether you prioritize weight-composition oriented protocols or energy and mitochondrial support priorities. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can MK-677 (Ibutamoren) and NAD+ be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next